Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 203 entries
Sorted by: Best Match Show Resources per page
Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal and anti-HIV activities.

Chemical biology & drug design

Ahmed N, Brahmbhatt KG, Khan SI, Jacob M, Tekwani BL, Sabde S, Mitra D, Singh IP, Khan IA, Bhutani KK.
PMID: 26404724
Chem Biol Drug Des. 2012 Jun 15; doi: 10.1111/j.1747-0285.2012.01427.x. Epub 2012 Jun 15.

Fifty analogues of batzelladine K were synthesized and evaluated for in vitro antimalarial (Plasmodium falciparum), antileishmanial (Leishmania donovani), antimicrobial (panel of bacteria and fungi), antiviral (HIV-1) activities. Analogues 14h and 20l exhibited potential antimalarial activity against chloroquine-sensitive D6 strain...

Cite
Ahmed N, Brahmbhatt KG, Khan SI, et al. Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal and anti-HIV activities. Chem Biol Drug Des. 2012;doi: 10.1111/j.1747-0285.2012.01427.x.
Ahmed, N., Brahmbhatt, K. G., Khan, S. I., Jacob, M., Tekwani, B. L., Sabde, S., Mitra, D., Singh, I. P., Khan, I. A., & Bhutani, K. K. (2012). Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal and anti-HIV activities. Chemical biology & drug design, . https://doi.org/10.1111/j.1747-0285.2012.01427.x
Ahmed, Nafees, et al. "Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal and anti-HIV activities." Chemical biology & drug design vol. (2012). doi: https://doi.org/10.1111/j.1747-0285.2012.01427.x
Ahmed N, Brahmbhatt KG, Khan SI, Jacob M, Tekwani BL, Sabde S, Mitra D, Singh IP, Khan IA, Bhutani KK. Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal and anti-HIV activities. Chem Biol Drug Des. 2012 Jun 15; doi: 10.1111/j.1747-0285.2012.01427.x. Epub 2012 Jun 15. PMID: 26404724.
Copy Download .nbib Format: NLM
Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?.

Advances in urology

Abrol S, Jairath A, Ganpule S, Ganpule A, Mishra S, Sabnis R, Desai M.
PMID: 26600802
Adv Urol. 2015;2015:926590. doi: 10.1155/2015/926590. Epub 2015 Oct 27.

Aim. To correlate findings of conventional cystoscopy with CT virtual cystoscopy (CTVC) in detecting bladder tumors and to evaluate accuracy of virtual cystoscopy in early detection of bladder cancer. Material and Method. From June 2013 to June 2014, 50...

Cite
Abrol S, Jairath A, Ganpule S, et al. Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?. Adv Urol. 2015;2015:926590doi: 10.1155/2015/926590.
Abrol, S., Jairath, A., Ganpule, S., Ganpule, A., Mishra, S., Sabnis, R., & Desai, M. (2015). Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?. Advances in urology, 2015926590. https://doi.org/10.1155/2015/926590
Abrol, Sachin, et al. "Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?." Advances in urology vol. 2015 (2015): 926590. doi: https://doi.org/10.1155/2015/926590
Abrol S, Jairath A, Ganpule S, Ganpule A, Mishra S, Sabnis R, Desai M. Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?. Adv Urol. 2015;2015:926590. doi: 10.1155/2015/926590. Epub 2015 Oct 27. PMID: 26600802; PMCID: PMC4639634.
Copy Download .nbib Format: NLM
Cooperative reactivity of early-late heterodinuclear transition metal complexes with polar organic substrates.

Chemistry (Weinheim an der Bergstrasse, Germany)

Gade LH, Memmler H, Kauper U, Schneider A, Fabre S, Bezougli I, Lutz M, Galka C, Scowen IJ, McPartlin M.
PMID: 10807180
Chemistry. 2000 Feb 18;6(4):692-708. doi: 10.1002/(sici)1521-3765(20000218)6:4<692::aid-chem692>3.0.co;2-2.

A comprehensive investigation into the cooperative reactivity of two chemically complementary metal-complex fragments in early-late heterodinuclear complexes has been carried out. Reaction of the partially fluorinated tripodal amidozirconium complexes [HC-(SiMe2NR)3Zr(mu-Cl)2Li(OEt2)2] (R = 2-FC6H4: 2a, 2,3,4-F3C6H4: 2b) with K[CpM(CO)2] (M=Fe,...

Cite
Gade LH, Memmler H, Kauper U, et al. Cooperative reactivity of early-late heterodinuclear transition metal complexes with polar organic substrates. Chemistry. 2000;6(4):692-708doi: 10.1002/(sici)1521-3765(20000218)6:4<692::aid-chem692>3.0.co;2-2.
Gade, L. H., Memmler, H., Kauper, U., Schneider, A., Fabre, S., Bezougli, I., Lutz, M., Galka, C., Scowen, I. J., & McPartlin, M. (2000). Cooperative reactivity of early-late heterodinuclear transition metal complexes with polar organic substrates. Chemistry (Weinheim an der Bergstrasse, Germany), 6(4), 692-708. https://doi.org/10.1002/(sici)1521-3765(20000218)6:4<692::aid-chem692>3.0.co;2-2
Gade, et al. "Cooperative reactivity of early-late heterodinuclear transition metal complexes with polar organic substrates." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 6,4 (2000): 692-708. doi: https://doi.org/10.1002/(sici)1521-3765(20000218)6:4<692::aid-chem692>3.0.co;2-2
Gade LH, Memmler H, Kauper U, Schneider A, Fabre S, Bezougli I, Lutz M, Galka C, Scowen IJ, McPartlin M. Cooperative reactivity of early-late heterodinuclear transition metal complexes with polar organic substrates. Chemistry. 2000 Feb 18;6(4):692-708. doi: 10.1002/(sici)1521-3765(20000218)6:4<692::aid-chem692>3.0.co;2-2. PMID: 10807180.
Copy Download .nbib Format: NLM
Penetration of chemicals into the oocyte, uterine fluid, and preimplantation blastocyst.

Environmental health perspectives

Fabro S.
PMID: 17539150
Environ Health Perspect. 1978 Jun;24:25-9. doi: 10.1289/ehp.782425.

Chemicals, including commonly used drugs (e.g., penicillin, meprobamate, pyridium, and mercaptomerin) penetrate and persist for some time in the ovarian follicular fluid at concentrations approximately similar to that of the serum. Information as to the penetration of chemicals into...

Cite
Fabro S. Penetration of chemicals into the oocyte, uterine fluid, and preimplantation blastocyst. Environ Health Perspect. 1978;24:25-9doi: 10.1289/ehp.782425.
Fabro, S. (1978). Penetration of chemicals into the oocyte, uterine fluid, and preimplantation blastocyst. Environmental health perspectives, 2425-9. https://doi.org/10.1289/ehp.782425
Fabro, S. "Penetration of chemicals into the oocyte, uterine fluid, and preimplantation blastocyst." Environmental health perspectives vol. 24 (1978): 25-9. doi: https://doi.org/10.1289/ehp.782425
Fabro S. Penetration of chemicals into the oocyte, uterine fluid, and preimplantation blastocyst. Environ Health Perspect. 1978 Jun;24:25-9. doi: 10.1289/ehp.782425. PMID: 17539150; PMCID: PMC1637222.
Copy Download .nbib Format: NLM
Mentorship programs for faculty development in academic general pediatric divisions.

International journal of pediatrics

Takagishi J, Dabrow S.
PMID: 22164177
Int J Pediatr. 2011;2011:538616. doi: 10.1155/2011/538616. Epub 2011 Nov 17.

Introduction. Mentoring relationships have been shown to support academicians in areas of research, work/life balance, and promotion. Methods. General pediatric division chiefs accessed an electronic survey asking about mentorship relationships, their ability to create a mentorship program, and resources...

Cite
Takagishi J, Dabrow S. Mentorship programs for faculty development in academic general pediatric divisions. Int J Pediatr. 2011;2011:538616doi: 10.1155/2011/538616.
Takagishi, J., & Dabrow, S. (2011). Mentorship programs for faculty development in academic general pediatric divisions. International journal of pediatrics, 2011538616. https://doi.org/10.1155/2011/538616
Takagishi, Jennifer, and Dabrow, Sharon. "Mentorship programs for faculty development in academic general pediatric divisions." International journal of pediatrics vol. 2011 (2011): 538616. doi: https://doi.org/10.1155/2011/538616
Takagishi J, Dabrow S. Mentorship programs for faculty development in academic general pediatric divisions. Int J Pediatr. 2011;2011:538616. doi: 10.1155/2011/538616. Epub 2011 Nov 17. PMID: 22164177; PMCID: PMC3228401.
Copy Download .nbib Format: NLM
Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre.

Therapeutic advances in respiratory disease

Condliffe R, Elliot CA, Hurdman J, Sabroe I, Billings C, Kiely DG, Hamilton N.
PMID: 24787237
Ther Adv Respir Dis. 2014 Jun;8(3):71-77. doi: 10.1177/1753465814532304. Epub 2014 Apr 30.

INTRODUCTION: Ambrisentan is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial hypertension (PAH). There are few data on clinical use and long-term tolerability in a wider range of patients with pulmonary hypertension (PH).METHODS: All patients...

Cite
Condliffe R, Elliot CA, Hurdman J, et al. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014;8(3):71-77doi: 10.1177/1753465814532304.
Condliffe, R., Elliot, C. A., Hurdman, J., Sabroe, I., Billings, C., Kiely, D. G., & Hamilton, N. (2014). Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Therapeutic advances in respiratory disease, 8(3), 71-77. https://doi.org/10.1177/1753465814532304
Condliffe, Robin, et al. "Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre." Therapeutic advances in respiratory disease vol. 8,3 (2014): 71-77. doi: https://doi.org/10.1177/1753465814532304
Condliffe R, Elliot CA, Hurdman J, Sabroe I, Billings C, Kiely DG, Hamilton N. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014 Jun;8(3):71-77. doi: 10.1177/1753465814532304. Epub 2014 Apr 30. PMID: 24787237.
Copy Download .nbib Format: NLM
Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fear.

Frontiers in behavioral neuroscience

Norrholm SD, Anderson KM, Olin IW, Jovanovic T, Kwon C, Warren VT, McCarthy A, Bosshardt L, Sabree J, Duncan EJ, Rothbaum BO, Bradley B.
PMID: 22125516
Front Behav Neurosci. 2011 Nov 21;5:77. doi: 10.3389/fnbeh.2011.00077. eCollection 2011.

Fear conditioning methodologies have often been employed as testable models for assessing learned fear responses in individuals with anxiety disorders such as post-traumatic stress disorder (PTSD) and specific phobia. One frequently used paradigm is measurement of the acoustic startle...

Cite
Norrholm SD, Anderson KM, Olin IW, et al. Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fear. Front Behav Neurosci. 2011;5:77doi: 10.3389/fnbeh.2011.00077.
Norrholm, S. D., Anderson, K. M., Olin, I. W., Jovanovic, T., Kwon, C., Warren, V. T., McCarthy, A., Bosshardt, L., Sabree, J., Duncan, E. J., Rothbaum, B. O., & Bradley, B. (2011). Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fear. Frontiers in behavioral neuroscience, 577. https://doi.org/10.3389/fnbeh.2011.00077
Norrholm, Seth D, et al. "Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fear." Frontiers in behavioral neuroscience vol. 5 (2011): 77. doi: https://doi.org/10.3389/fnbeh.2011.00077
Norrholm SD, Anderson KM, Olin IW, Jovanovic T, Kwon C, Warren VT, McCarthy A, Bosshardt L, Sabree J, Duncan EJ, Rothbaum BO, Bradley B. Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fear. Front Behav Neurosci. 2011 Nov 21;5:77. doi: 10.3389/fnbeh.2011.00077. eCollection 2011. PMID: 22125516; PMCID: PMC3221285.
Copy Download .nbib Format: NLM
Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape.

Neurosurgery

Zinn PO, Singh SK, Kotrotsou A, Abrol S, Thomas G, Mosley J, Elakkad A, Hassan I, Kumar A, Colen RR.
PMID: 28899058
Neurosurgery. 2017 Sep 01;64:203-210. doi: 10.1093/neuros/nyx316.

No abstract available.

Cite
Zinn PO, Singh SK, Kotrotsou A, et al. Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. Neurosurgery. 2017;64:203-210doi: 10.1093/neuros/nyx316.
Zinn, P. O., Singh, S. K., Kotrotsou, A., Abrol, S., Thomas, G., Mosley, J., Elakkad, A., Hassan, I., Kumar, A., & Colen, R. R. (2017). Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. Neurosurgery, 64203-210. https://doi.org/10.1093/neuros/nyx316
Zinn, Pascal O, et al. "Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape." Neurosurgery vol. 64 (2017): 203-210. doi: https://doi.org/10.1093/neuros/nyx316
Zinn PO, Singh SK, Kotrotsou A, Abrol S, Thomas G, Mosley J, Elakkad A, Hassan I, Kumar A, Colen RR. Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. Neurosurgery. 2017 Sep 01;64:203-210. doi: 10.1093/neuros/nyx316. PMID: 28899058; PMCID: PMC6433436.
Copy Download .nbib Format: NLM
Misuse of topical corticosteroids on facial skin. A study of 200 patients.

Journal of dermatological case reports

Sharma R, Abrol S, Wani M.
PMID: 28539982
J Dermatol Case Rep. 2017 Mar 31;11(1):5-8. doi: 10.3315/jdcr.2017.1240. eCollection 2017 Mar 31.

BACKGROUND: Topical corticosteroids have become available as over the counter drugs and are widely misused for various conditions.OBJECTIVE: The aim of this study is to assess the clinical and epidemiological aspects of the unjustified use of topical corticosteroids for...

Cite
Sharma R, Abrol S, Wani M. Misuse of topical corticosteroids on facial skin. A study of 200 patients. J Dermatol Case Rep. 2017;11(1):5-8doi: 10.3315/jdcr.2017.1240.
Sharma, R., Abrol, S., & Wani, M. (2017). Misuse of topical corticosteroids on facial skin. A study of 200 patients. Journal of dermatological case reports, 11(1), 5-8. https://doi.org/10.3315/jdcr.2017.1240
Sharma, Rohini, et al. "Misuse of topical corticosteroids on facial skin. A study of 200 patients." Journal of dermatological case reports vol. 11,1 (2017): 5-8. doi: https://doi.org/10.3315/jdcr.2017.1240
Sharma R, Abrol S, Wani M. Misuse of topical corticosteroids on facial skin. A study of 200 patients. J Dermatol Case Rep. 2017 Mar 31;11(1):5-8. doi: 10.3315/jdcr.2017.1240. eCollection 2017 Mar 31. PMID: 28539982; PMCID: PMC5439689.
Copy Download .nbib Format: NLM
Thymectomy lowers the myasthenia gravis biomarker miR-150-5p.

Neurology(R) neuroimmunology & neuroinflammation

Molin CJ, Sabre L, Weis CA, Punga T, Punga AR.
PMID: 29511707
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e450. doi: 10.1212/NXI.0000000000000450. eCollection 2018 May.

OBJECTIVE: The aim of the study was to analyze the effect of thymectomy on the proposed disease-specific microRNA (miRNA) biomarkers miR-150-5p and miR-21-5p in patients from the prospective randomized trial of thymectomy in myasthenia gravis (MGTX trial) and to...

Cite
Molin CJ, Sabre L, Weis CA, et al. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e450doi: 10.1212/NXI.0000000000000450.
Molin, C. J., Sabre, L., Weis, C. A., Punga, T., & Punga, A. R. (2018). Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurology(R) neuroimmunology & neuroinflammation, 5(3), e450. https://doi.org/10.1212/NXI.0000000000000450
Molin, Carl Johan, et al. "Thymectomy lowers the myasthenia gravis biomarker miR-150-5p." Neurology(R) neuroimmunology & neuroinflammation vol. 5,3 (2018): e450. doi: https://doi.org/10.1212/NXI.0000000000000450
Molin CJ, Sabre L, Weis CA, Punga T, Punga AR. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e450. doi: 10.1212/NXI.0000000000000450. eCollection 2018 May. PMID: 29511707; PMCID: PMC5833334.
Copy Download .nbib Format: NLM
Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.

Therapeutic advances in musculoskeletal disease

Espinoza F, Fabre S, Pers YM.
PMID: 27493689
Ther Adv Musculoskelet Dis. 2016 Aug;8(4):107-18. doi: 10.1177/1759720X16654476. Epub 2016 Jun 13.

Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks,...

Cite
Espinoza F, Fabre S, Pers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):107-18doi: 10.1177/1759720X16654476.
Espinoza, F., Fabre, S., & Pers, Y. M. (2016). Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Therapeutic advances in musculoskeletal disease, 8(4), 107-18. https://doi.org/10.1177/1759720X16654476
Espinoza, Francisco, et al. "Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications." Therapeutic advances in musculoskeletal disease vol. 8,4 (2016): 107-18. doi: https://doi.org/10.1177/1759720X16654476
Espinoza F, Fabre S, Pers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):107-18. doi: 10.1177/1759720X16654476. Epub 2016 Jun 13. PMID: 27493689; PMCID: PMC4959628.
Copy Download .nbib Format: NLM
Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Frontiers in microbiology

Hatoum R, Labrie S, Fliss I.
PMID: 23267352
Front Microbiol. 2012 Dec 19;3:421. doi: 10.3389/fmicb.2012.00421. eCollection 2012.

The yeasts constitute a large and heterogeneous group of microorganisms that are currently attracting increased attention from scientists and industry. Numerous and diverse biological activities make them promising candidates for a wide range of applications not limited to the...

Cite
Hatoum R, Labrie S, Fliss I. Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Front Microbiol. 2012;3:421doi: 10.3389/fmicb.2012.00421.
Hatoum, R., Labrie, S., & Fliss, I. (2012). Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Frontiers in microbiology, 3421. https://doi.org/10.3389/fmicb.2012.00421
Hatoum, Rima, et al. "Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications." Frontiers in microbiology vol. 3 (2012): 421. doi: https://doi.org/10.3389/fmicb.2012.00421
Hatoum R, Labrie S, Fliss I. Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Front Microbiol. 2012 Dec 19;3:421. doi: 10.3389/fmicb.2012.00421. eCollection 2012. PMID: 23267352; PMCID: PMC3525881.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 203 entries